TICKERNOMICS Sign up
Last Update: 2024-12-27 15:25:51
ANAPTYSBIO INC ( ANAB ) https://www.anaptysbio.com
13.74USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-36.54%
ANAB
SPY
32.66%
-61.76%
ANAB
SPY
108.59%
-18.02%
ANAB
SPY
302.52%
ANAB
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
401.32
-12.30
0.39
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.42
7.02
4.76
-10.11
0.00
0.10
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-75.81
98.01
-161.27
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.872
-90.48
-25.63
0.15
Other Earnings and Cash Flow Stats:
ANAPTYSBIO INC ( ANAB ) Net Income TTM ($MM) is -165.66
ANAPTYSBIO INC ( ANAB ) Operating Income TTM ($MM) is -147.41
ANAPTYSBIO INC ( ANAB ) Owners' Earnings Annual ($MM) is 0.00
ANAPTYSBIO INC ( ANAB ) Current Price to Owners' Earnings ratio is 0.00
ANAPTYSBIO INC ( ANAB ) EBITDA TTM ($MM) is -145.46
ANAPTYSBIO INC ( ANAB ) EBITDA Margin is -161.27%
Capital Allocation:
ANAPTYSBIO INC ( ANAB ) has paid 0.00 dividends per share and bought back -2.347 million shares in the past 12 months
ANAPTYSBIO INC ( ANAB ) has reduced its debt by 1.74 million USD in the last 12 months
Capital Structure:
ANAPTYSBIO INC ( ANAB ) Interest-bearing Debt ($MM) as of last quarter is 16
ANAPTYSBIO INC ( ANAB ) Annual Working Capital Investments ($MM) are 31
ANAPTYSBIO INC ( ANAB ) Book Value ($MM) as of last quarter is 84
ANAPTYSBIO INC ( ANAB ) Debt/Capital as of last quarter is 19%
Other Balance Sheet Stats:
ANAPTYSBIO INC ( ANAB ) has 191 million in cash on hand as of last quarter
ANAPTYSBIO INC ( ANAB ) has 43 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ANAPTYSBIO INC ( ANAB ) has 28 common shares outstanding as of last quarter
ANAPTYSBIO INC ( ANAB ) has 0 million USD of preferred stock value
Academic Scores:
ANAPTYSBIO INC ( ANAB ) Altman Z-Score is -1.22 as of last quarter
ANAPTYSBIO INC ( ANAB ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
ANAPTYSBIO INC ( ANAB ) largest shareholder is owning shares at 0.00 ($MM) value
RENTON HOLLINGS(an insider) Sold 10000 shares of ANAPTYSBIO INC ( ANAB ) for the amount of $250000.00 on 2024-11-29
1.74% of ANAPTYSBIO INC ( ANAB ) is held by insiders, and 101.04% is held by institutions
ANAPTYSBIO INC ( ANAB ) went public on 2017-01-26
Other ANAPTYSBIO INC ( ANAB ) financial metrics:
FCF:-96.45
Unlevered Free Cash Flow:0.00
EPS:-4.55
Operating Margin:-75.81
Gross Profit Margin:98.01
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-155.75
Beta:0.15
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ANAPTYSBIO INC ( ANAB ) :
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.